Saturday 17 October 2026
Export ARTL’s income statement to Excel — free account
Artelo Biosciences, Inc.
ARTL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.7% and free cash flow fell 879.2%, each against the same quarter a year earlier.
2.70
0.04
−1.46%
Follow ARTL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Aug '22 | Aug '21 | Aug '20 | Aug '19 | Aug '18 | Aug '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.17 | 1.44 | 8.51 | 18.36 | 18.36 | 19.61 | 4.66 | 4.35 | 0.75 | 19.53 |
Net Debt/EBITDA |
0.05 | 0.23 | 1.05 | 1.56 | 1.70 | 1.35 | 0.46 | 1.38 | 0.14 | 2.47 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.66 | 0.85 | 0.88 | 0.79 | 0.79 | 0.83 | 0.93 | 1.29 | 0.69 | 0.92 |
Capex/Depreciation |
(0.30) | — | — | — | — | — | 0.00 | (3,001.40) | (2.67) | 0.00 |
Interest Coverage |
(41.17) | — | — | (2,057.40) | (10,287.00) | (3,720.50) | (4,686.00) | — | — | (110.86) |
| (1,625.11%) | (134.52%) | (59.63%) | (51.97%) | (64.13%) | (93.45%) | (99.72%) | (81.57%) | (1,143.73%) | (88.47%) | |
| (343.49%) | (110.77%) | (55.51%) | (49.37%) | (61.00%) | (87.44%) | (85.74%) | (63.15%) | (482.55%) | (81.80%) | |
ROIC |
0.00% | (1,217.24%) | (468.04%) | (191.07%) | 0.00% | (235.24%) | (169.00%) | (193.40%) | 0.00% | 0.00% |
Return on Tangible Assets |
384.56% | (1,251.72%) | (95.87%) | (58.20%) | (58.20%) | (75.96%) | (253.54%) | (63.48%) | 1,735.93% | (43.11%) |
Average Days of Receivables |
— | — | — | — | — | — | — | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.73 | 0.43 | 0.16 | 0.10 | 0.10 | 0.16 | 0.47 | 0.31 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(225.25) | (419.60) | (448.47) | (457.60) | (2.81) | (797.53) | (2,898.00) | (4,770.44) | (3,221.60) | (60.22) |
Cash per Share |
15.75 | 117.49 | 569.73 | 916.46 | 6.19 | 1,307.14 | 1,428.00 | 4,915.56 | 674.80 | 159.11 |
Shareholders Equity per Share |
(33.39) | 143.57 | 642.19 | 1,108.74 | 6.85 | 1,563.90 | 2,583.33 | 6,068.00 | (270.00) | 151.33 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(33.39) | 143.57 | 642.19 | 1,108.74 | 6.85 | 1,563.90 | 2,583.33 | 6,068.00 | (270.00) | 151.33 |
Free Cash Flow |
(8.58) | (8.35) | (8.21) | (8.01) | (7.96) | (6.14) | (4.35) | (4.29) | (1.61) | (0.22) |
Working Capital |
(3.35) | 0.79 | 9.69 | 17.32 | 17.32 | 9.79 | 1.84 | 3.42 | (0.14) | 0.54 |
Capital Expenditures |
(0.06) | — | — | — | — | — | — | (1.50) | 0.00 | — |
Net Current Asset Value |
(3.38) | 0.72 | 9.69 | 17.30 | 17.30 | 9.72 | 1.84 | 3.42 | (0.14) | 0.54 |
| Other line items | ||||||||||
Quick Ratio |
0.15 | 1.32 | 8.08 | 16.07 | 17.57 | 19.14 | 4.28 | 4.33 | 0.68 | 19.48 |
Depreciation/Fixed assets |
0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.71 | 0.50 | 0.00 |
Cash ROIC |
1,277.08% | (160.73%) | (37.01%) | (22.60%) | (21.56%) | (27.78%) | (72.25%) | (43.43%) | (795.85%) | (19.40%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(223.62) | (419.60) | (448.47) | (457.60) | (2.81) | (797.53) | (2,898.00) | (3,103.00) | (3,220.00) | (60.22) |
Capex per Share |
(1.63) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1,667.44) | (1.60) | 0.00 |
Average Receivables |
— | — | — | — | — | — | — | 0.02 | 0.02 | — |
Average Payables |
2.36 | 1.46 | 1.07 | 0.69 | — | 0.48 | 0.42 | 0.44 | 0.28 | 0.02 |
Average Assets |
3.75 | 8.87 | 16.73 | 20.42 | 16.53 | 8.51 | 5.43 | 3.44 | 0.49 | 0.29 |
Average Common Equity |
0.79 | 7.30 | 15.58 | 19.40 | 15.72 | 7.96 | 4.67 | 2.66 | 0.20 | 0.27 |
Capex to Sales |
0.00 | — | — | — | — | — | — | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 28 Sep 2026